Chang Gon Kim
2025–2025 OpenAlex profile ↗
Reproducibility track record
1
assessed papers
88/100
mean reproducibility
1
reproduced (C1–C2)
0
flagged
3
total citations
flag rate:
0%
(0/1)
The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.
Authorship role
first author: 0
last author: 0
Topics
Funders
—
Frequent co-authors
Heejin Nam 1Seung Il Kim 1Su‐Hyung Park 1Minyong Kang 1Minwoo Jeon 1Jung‐Yun Lee 1Sun‐ju Byeon 1Seong Il Seo 1Kee Yang Chung 1Shin Hwang 1
Institutions
CHA University Bundang Medical Center 1Seoul National University Bundang Hospital 1Daejeon Sun Hospital 1Korea Advanced Institute of Science and Technology 1Ajou University 1Yonsei University 1
Geography (author institutions)
KR 1
Co-author network
Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.
How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.
Assessed papers (1)
Complete publication record (49)
Request a reproduction →1 assessed by us (1 reproduced) · 48 not yet assessed — every PubMed paper on record, linked below.
-
Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinomaCell Reports Medicine · 2025 · PMID 40961944L1 88/100
-
Organ‐Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study ↗Cancer Medicine · 2025 · PMID 40488227not yet assessed
-
Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS study ↗Lung Cancer · 2025 · PMID 41202701not yet assessed
-
Impact of HER2-positivity on prognosis and targeted therapeutic outcomes in advanced biliary tract cancer. ↗Journal of Clinical Oncology · 2025not yet assessed
-
Organ-specific responses to nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma: A multicenter, retrospective study. ↗Journal of Clinical Oncology · 2025not yet assessed
-
Efficacy and safety of ifosfamide and mesna in metastatic castration-resistant prostate cancer after taxane-based chemotherapy and novel hormonal therapy failure. ↗Journal of Clinical Oncology · 2025not yet assessed
-
Phase 1 dose escalation (DEs) & expansion (DEx) study to evaluate the safety & efficacy of IDE397 plus sacituzumab-govitecan in patients with advanced urothelial carcinoma (UC) with MTAP deletion (MTAPdel). ↗Journal of Clinical Oncology · 2025not yet assessed
-
Abstract 5864: Preclinical investigation of anti-tumor efficacy of allogeneic natural killer cells combined with cetuximab for head and neck squamous cell carcinoma ↗Cancer Research · 2025not yet assessed
-
Neoadjuvant lazertinib with or without chemotherapy for patients with epidermal growth factor receptor ( EGFR )-mutated resectable non-small cell lung cancer (NSCLC): NeoLazer trial. ↗Journal of Clinical Oncology · 2025not yet assessed
-
Efficacy and Safety of Ifosfamide and Mesna in Metastatic Castration-Resistant Prostate Cancer after Taxane-Based Chemotherapy and Novel Hormonal Therapy Failure ↗Cancer Research and Treatment · 2025 · PMID 40506027not yet assessed
-
Neoadjuvant chemotherapy followed by definitive local treatment in locally advanced sinonasal squamous cell carcinoma ↗Frontiers in Oncology · 2024 · PMID 39529826not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung Cancer ↗International Journal of Radiation Oncology*Biology*Physics · 2022 · PMID 35896144not yet assessed
-
PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors ↗Clinical Cancer Research · 2020 · PMID 31941832not yet assessed
-
Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small cell lung cancer. ↗Journal of Clinical Oncology · 2020not yet assessed
-
4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8+ T Cells in Hepatocellular Carcinoma ↗Hepatology · 2019 · PMID 31353502not yet assessed
-
Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8+ T Cells is Determined by Their Differentiation Status in Glioblastoma ↗Clinical Cancer Research · 2019 · PMID 30659023not yet assessed
-
Abstract C132: Fusobacterium nucleatum in colorectal carcinoma and expression of multiple immune checkpoint molecules on T cells ↗Molecular Cancer Therapeutics · 2019not yet assessed
-
Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma ↗OncoImmunology · 2018 · PMID 30546966not yet assessed
-
IMMU-13. EFFECT OF COMBINED ANTI-PD-1 AND TEMOZOLOMIDE THERAPY IN GLIOBLASTOMA ↗Neuro-Oncology · 2018not yet assessed
-
IMMU-16. EFFECT OF ANTI-PD-1 THERAPY COMBINATION ON TEMOZOLOMIDE IN MOUSE GLIOBLASTOMA ↗Neuro-Oncology · 2017not yet assessed
Full bibliography from OpenAlex; reproducibility verdicts matched by PMID.
Author attribution follows OpenAlex disambiguation, which is imperfect — a researcher's papers can be split across profiles or mixed with a namesake.
No ORCID on record to anchor it (≈⅓ of researchers have none), so this rests on name disambiguation alone. See every “Kim C” paper on PubMed ↗